Disposition of 3000 shares by Andrew Hykes of Inari Medical at 50.83 subject to Rule 16b-3
NARIDelisted Stock | USD 79.97 0.00 0.00% |
Under 56% of Inari Medical's investor base is looking to short. The analysis of current outlook of investing in Inari Medical suggests that many traders are alarmed regarding Inari Medical's prospects. Inari Medical's investing sentiment shows overall attitude of investors towards Inari Medical.
Inari |
Filed transaction by Inari Medical Director, Officer: President And Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at investing.com
![]() |
Inari Medical Fundamental Analysis
We analyze Inari Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inari Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inari Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Inari Medical is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Inari Medical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Inari Medical stock to make a market-neutral strategy. Peer analysis of Inari Medical could also be used in its relative valuation, which is a method of valuing Inari Medical by comparing valuation metrics with similar companies.
Peers
Inari Medical Related Equities
PGNY | Progyny | 3.64 | ||||
LEGN | Legend Biotech | 0.73 | ||||
OM | Outset Medical | 9.69 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Inari Stock
If you are still planning to invest in Inari Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Inari Medical's history and understand the potential risks before investing.
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |